Trends in Clinical Oncology
Part II: Glues and Degrader Therapeutics: Evolution, Clinical Successes, and Next-Generation Designs
Thursday, November 12, 2026 | 11:00am EST | 8:00am PST
Targeted protein degradation is rapidly evolving from a novel therapeutic concept into a clinically validated platform capable of addressing traditionally difficult-to-drug proteins and mechanisms of therapeutic resistance. This webinar will examine the evolution of molecular glues and heterobifunctional degraders, including PROTACs, from early discoveries with thalidomide and cereblon to recent clinical advances and the first regulatory validation of rational target degradation. We will explore how ternary-complex formation, E3-ligase biology, degradation kinetics, tissue distribution, and biomarker selection influence therapeutic efficacy and safety.
Emerging strategies – including rational molecular-glue discovery, tissue-selective E3 recruitment, next-generation linker engineering, degrader-antibody conjugates, and expansion beyond proteasomal degradation – will also be discussed. The session will highlight opportunities for integrating translational science, clinical biomarkers, and drug development strategies to improve therapeutic index and accelerate the development of next-generation degrader therapeutics.
What you will learn:
- How molecular glues and PROTACs have evolved from early discoveries into clinically validated approaches for targeted protein degradation.
- You will understand the key scientific and translational factors that influence degrader efficacy and safety, including ternary-complex formation, E3-ligase biology, degradation kinetics, tissue distribution, and biomarker selection.
- You will explore next-generation strategies—such as rational molecular-glue discovery, tissue-selective E3 recruitment, degrader-antibody conjugates, and broader degradation pathways—that may improve therapeutic index and accelerate drug development.
Part III: Targeting Cancer Metabolism: Emerging Vulnerabilities and New Opportunities in Precision Oncology
Thursday, December 10, 2026 | 11:00am EST | 8:00am PST
Cancer cells rely on distinct metabolic adaptations to survive, proliferate, and evade treatment, creating new opportunities for more precise, targeted therapies. Yet translating these vulnerabilities into effective treatments remains challenging as tumors adapt, metabolic pathways overlap, and targets may also be shared with healthy tissues.
Join this webinar to explore established and emerging strategies in cancer metabolism, from IDH inhibition and synthetic lethality to nutrient dependencies, ferroptosis, and tumor–immune metabolic interactions. Discover how biomarker-driven patient selection, metabolic profiling, and rational combinations are helping researchers identify actionable vulnerabilities, overcome resistance, and improve therapeutic outcomes.
What You’ll Learn:
How cancer metabolism is revealing new tumor-specific therapeutic vulnerabilities
The potential of IDH inhibition, MTAP–MAT2A–PRMT5 synthetic lethality, nutrient dependencies, ferroptosis, and immune-metabolic approaches
How biomarkers, metabolic profiling, and combination strategies can help address resistance and improve therapeutic outcomes
Part IV: Cell-Cycle Inhibitor Therapeutics: Evolution, Clinical Successes, and Next-Generation Designs
Thursday, January 14, 2027
Now Available On-Demand
- How ADCs have evolved from early cytotoxic delivery systems to next-generation therapeutic platforms with improved design and clinical utility.
- Which biological and pharmacologic factors influence ADC performance, including target expression, linker stability, payload properties, drug-to-antibody ratio, and tumor heterogeneity.
- What emerging strategies are being used to improve efficacy, manage toxicity, address resistance, and expand the therapeutic potential of ADCs in oncology.
Speakers
